DelMar Approved to Start China Phase II Trial of Brain Cancer Treatment

DelMar Pharma, a Canada-US biopharma, was approved to start a China Phase II trial of its lead candidate, VAL-083, which targets glioblastoma multiforme (GBM). The trial will test VAL-083 as a first-line GBM treatment in patients with newly diagnosed MGMT-unmethylated disease. Because the trial uses a patient's MGMT status as a biomarker, it required approval from China's Human Genetic Resources Administration. DelMar is partnering new China indications for VAL-083 with Guangxi Wuzhou Pharma, which already markets the drug in China for leukemia and lung cancer. More details.... Stock Symbol: (NSDQ: DMPI) Share this with colleagues: // //